1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Northern Light Pharmaceuticals AB - Product Pipeline Review - 2014

Northern Light Pharmaceuticals AB - Product Pipeline Review - 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 18 pages

Northern Light Pharmaceuticals AB - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Northern Light Pharmaceuticals AB - Product Pipeline Review - 2014’, provides an overview of the Northern Light Pharmaceuticals AB’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Northern Light Pharmaceuticals AB’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Northern Light Pharmaceuticals AB including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Northern Light Pharmaceuticals AB’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Northern Light Pharmaceuticals AB’s pipeline products

Reasons to buy

- Evaluate Northern Light Pharmaceuticals AB’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Northern Light Pharmaceuticals AB in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Northern Light Pharmaceuticals AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Northern Light Pharmaceuticals AB and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Northern Light Pharmaceuticals AB
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Northern Light Pharmaceuticals AB and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Northern Light Pharmaceuticals AB - Product Pipeline Review - 2014
Table of Contents

Northern Light Pharmaceuticals AB Snapshot 4
Northern Light Pharmaceuticals AB Overview 4
Key Information 4
Key Facts 4
Northern Light Pharmaceuticals AB - Research and Development Overview 5
Key Therapeutic Areas 5
Northern Light Pharmaceuticals AB - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Northern Light Pharmaceuticals AB - Pipeline Products Glance 9
Northern Light Pharmaceuticals AB - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Northern Light Pharmaceuticals AB - Drug Profiles 10
Small Molecule to Antagonize Chemokine Receptor for Cancer Pain 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
Small Molecule to Inhibit Prostaglandin E2 for Pain 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Small Molecule to Inhibit Secretase for Alzheimer's Disease 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Northern Light Pharmaceuticals AB - Pipeline Analysis 13
Northern Light Pharmaceuticals AB - Pipeline Products by Target 13
Northern Light Pharmaceuticals AB - Pipeline Products by Molecule Type 14
Northern Light Pharmaceuticals AB - Pipeline Products by Mechanism of Action 15
Northern Light Pharmaceuticals AB - Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
Coverage 17
Secondary Research 17
Primary Research 17
Expert Panel Validation 17
Contact Us 18
Disclaimer 18

List of Tables

Northern Light Pharmaceuticals AB, Key Information 4
Northern Light Pharmaceuticals AB, Key Facts 4
Northern Light Pharmaceuticals AB - Pipeline by Indication, 2014 6
Northern Light Pharmaceuticals AB - Pipeline by Stage of Development, 2014 7
Northern Light Pharmaceuticals AB - Monotherapy Products in Pipeline, 2014 8
Northern Light Pharmaceuticals AB - Preclinical, 2014 9
Northern Light Pharmaceuticals AB - Pipeline by Target, 2014 13
Northern Light Pharmaceuticals AB - Pipeline by Molecule Type, 2014 14
Northern Light Pharmaceuticals AB - Pipeline Products by Mechanism of Action, 2014 15

List of Figures

Northern Light Pharmaceuticals AB - Pipeline by Top 10 Indication, 2014 6
Northern Light Pharmaceuticals AB - Pipeline by Top 10 Target, 2014 13
Northern Light Pharmaceuticals AB - Pipeline Products by Top 10 Mechanism of Action, 2014 15

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.